2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

May 9 | 2022

2cureX is pioneering drug sensitivity testing for the individualized selection of cancer treatment. The company has been invited to present the IndiTreat® test and associated clinical data at a seminar organized by the Society for Precision Medicine (SFPM) on 11 May 2022, together with its clinical partner, University Hospital Vejle,.

2cureX has led the development of functional drug sensitivity testing in oncology for the past 15 years. While this was previously viewed largely as a research tool, the medical community recognizes increasingly its significant role in individualizing the treatment of cancer patients. This realization led to the Dana-Faber Cancer Institute, Harvard Medical School (Boston, US) and the Fred Hutchinson Cancer Research Center (Seattle, US) establishing the Society for Functional Precision Medicine (www.sfpm.io). The society’s mission is “to improve patient care and outcomes by facilitating implementation of functional assays into clinical care”.

Ole Thastrup, CSO and Founder of 2cureX: “Drug sensitivity testing is an all-new In-Vitro Diagnostic concept. To establish broad clinical acceptance, it is of tremendous value that prestigious international cancer institutions like the Dana-Farber Cancer Institute, Harvard Medical School and Fred Hutchinson Cancer Center recognize the potential of dynamic functional testing.” He continues: “It is an honor to be invited to present the clinical value of IndiTreat® in metastatic colorectal cancer at SFPM, and a pleasure to do so together with our long-term clinical partner, University Hospital Vejle, who recognized the value of this concept before most other cancer hospitals.”

Fernando Andreu, CEO of 2cureX comments “Through their activities and influence, the Society for Functional Precision Medicine is playing a key role in moving drug sensitivity testing to mainstream diagnostics. Our participation in this event is strong support for the ongoing rollout of IndiTreat® in hospitals across Europe”.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The portfolio of IndiTreat® tests is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® mCRC Start for first line of therapy, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se